Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. - overview
Established
2000
Location
Shijiazhuang, Hebei, China
Primary Industry
Biopolymers
About
Based in Shijiazhuang, China and established in 2000, Hebei Changshan Biochemical Pharmaceutical Co. , Ltd. is a biochemical pharmaceuticals developer that focuses on heparin drugs research and sells heparin products. The company has set up 10 subsidiaries.
In 2018, it was selected by China Shuangchuang as a typical model enterprise of entrepreneurship and innovation in China. The company has established a research team with more than 200 R&D personnel, of which about 40% are with master's degree or above. As of December 2023, it has 37 authorised patents and 28 patents under application. In 2008, SDIC Unity Capital invested CNY 30 million in the company.
In 2011, Changshan Biochemical was listed on the Shenzhen Stock Exchange. Hebei Changshan Biochemical Pharmaceutical Co. , Ltd. is engaged in the research, development and manufacture of heparin APIs, heparin preparations and healthcare products.
Its main products include heparin sodium API, low molecular weight heparin calcium injection, heparin sodium injection, hard capsule formulations and Yihaitang capsules. Its drugs are used in the treatment of therapeutic cardiovascular diseases, diabetes and cancer. The company is also involved in the fields of medical devices, cosmetology and precision medicine. The company generates revenue by developing and offering heparin sodium API, low molecular weight heparin calcium injection, heparin sodium injection, hard capsule and Yihaitang capsule and other drugs.
Current Investors
SDIC Unity Capital
Primary Industry
Biopolymers
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.hbcsbio.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IPO | Completed | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | - | ||||||||
| Growth | Completed | Hebei Changshan Biochemical Pharmaceutical Co., Ltd. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.